Celltrion: A Korean Biosimilars Pioneer
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Founded in November 2010, P&K Skin Research Center was established to provide scientific and systematic technical support and information according to various customers’ demands about clinical tests for developing new ingredients as well as functional cosmetics and quasi-drugs. P&K Skin Research Center started through a strategic alliance with Daebong LS Ltd, which is the only company manufacturing and selling pharmaceutical and cosmetic and healthy functional food ingredients, and Chung-ang University Research Center for Medical Scieces, which was the first research center to own a general hospital in Korea.
P&K Skin Research Center is equipped with facilities that meet not only the KFDA and EU guidelines but also US standards. Through analyzing all functional stroma and protocol from physical through to chemical inspection techniques for pharmaceutical ingredients, and through 30 years’ history of Daebong LS, we clinically test efficacy of general cosmetic and functional ingredients and cosmetics in accordance with KFDA, EU and US guidelines. Through these scientific evaluations, we are trying to provide scientific technical support and information for consumer satisfaction about products directly applied to the skin.
We do our utmost to ensure scientific validity, objectivity and also transparency for efficacy and functionality evaluation with Daebong LS, which has abundant clinical experiences at manufacturing and analysis, especially for pharmaceutical and cosmetic ingredients, and our experts include a dermatologist of a university hospital who has various clinical test experiences.
Contact details:
City B/D 2F, 118-2 Heukseok-dong, Dongjak-gu, Seoul 156-860 Korea
+82 2 6295 1501~3
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the…
Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s…
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand…
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D. Cho also compares the challenges of the Chinese market with the potential…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…

See our Cookie Privacy Policy Here